Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Adcendo
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07362888 |
ADCE-B05-001 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2026-12-31 |
12% |
2026-01-24 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|